|
| Press Releases |
|
 |
|
| Thursday, August 4, 2022 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
| Wednesday, June 22, 2022 |
|
|
Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal |
| Eisai Co., Ltd. today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (Abeta) protofibril antibody lecanemab in people living with early Alzheimer's disease (AD) using a validated disease simulation model. more info >> |
|
| Monday, June 6, 2022 |
|
|
Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting |
| Eisai Co., Ltd. announced today new investigational data from the platinum-resistant ovarian cancer (PROC) cohort expansion of a Phase 1 study (Study 101) evaluating the antibody drug conjugate (ADC) co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202). more info >> |
|
| Friday, June 3, 2022 |
|
|
Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting |
| Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States. more info >> |
|
| Friday, May 27, 2022 |
|
|
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO22), which is taking place virtually and in-person in Chicago from June 3 to 7. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
EdgePoint Towers Appoints Ravin Vickneswaran as Chief Operating Officer 
Apr 2, 2025 11:00 HKT/SGT
|
|
|
Avenix Fzco Introduces Avexbot: Data-Driven Precision for Forex Traders
Apr 2, 2025 08:00 HKT/SGT
|
|
|
Euro Manganese Announces Upsize to Previously Announced Financing of up to C$11.2m (A$12.3m) including a Private Placement with Eric Sprott
Apr 1, 2025 22:39 HKT/SGT
|
|
|
Wuling Motors (00305.HK) Achieves a Surge of 115.6% in Net Profit Attributable to Shareholders for 2024
Apr 1, 2025 21:53 HKT/SGT
|
|
|
Baguio Green Group Announces 2024 Annual Results
Apr 1, 2025 20:19 HKT/SGT
|
|
|
analytica Vietnam 2025 Opens Tomorrow: The Leading Laboratory Exhibition Returns to Vietnam
Apr 1, 2025 20:01 HKT/SGT
|
|
|
Sunshine Insurance: Practicing 'Insurance for the People'
Apr 1, 2025 18:50 HKT/SGT
|
|
|
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 1, 2025 18:46 JST
|
|
|
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 1, 2025 18:38 JST
|
|
|
Quam Greater China Magnificent 7 Makes a Stunning Debut: Don't Miss the Next Wave of China Investment Opportunities
Apr 1, 2025 17:27 HKT/SGT
|
|
|
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 1, 2025 17:52 JST
|
|
|
FOURTH PARADIGM ANNOUNCES 2024 ANNUAL RESULTS
Apr 1, 2025 16:51 HKT/SGT
|
|
|
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 1, 2025 16:15 JST
|
|
|
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 1, 2025 14:59 JST
|
|
|
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 1, 2025 14:16 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
